Tower Research Capital LLC (Trc) Supernus Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,274 shares of SUPN stock, worth $82,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,274

Previous 9,124 75.08%

Holding current value

$82,364

Previous $244,000 71.31%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $176,524 - $240,845	-6,850 Reduced 75.08%	2,274 $70,000
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $226,788 - $295,375	8,726 Added 2192.46%	9,124 $244,000
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $546,103 - $708,464	-20,144 Reduced 98.06%	398 $13,000
Q4 2023 Feb 13, 2024	BUY	$22.72 - $29.68 $435,496 - $568,906	19,168 Added 1395.05%	20,542 $594,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $83,730 - $99,947	-3,037 Reduced 68.85%	1,374 $37,000
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $92,242 - $119,443	3,084 Added 232.4%	4,411 $132,000
Q1 2023 May 09, 2023	BUY	$34.93 - $42.03 $36,886 - $44,383	1,056 Added 389.67%	1,327 $48,000
Q4 2022 Feb 10, 2023	SELL	$31.09 - $37.88 $110,711 - $134,890	-3,561 Reduced 92.93%	271 $9,000
Q3 2022 Nov 10, 2022	BUY	$28.79 - $35.41 $43,472 - $53,469	1,510 Added 65.03%	3,832 $130,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $50,052 - $67,678	1,976 Added 571.1%	2,322 $67,000
Q1 2022 May 12, 2022	SELL	$28.51 - $32.9 $81,053 - $93,534	-2,843 Reduced 89.15%	346 $11,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $58,462 - $75,865	2,217 Added 228.09%	3,189 $93,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $38,699 - $51,605	-1,644 Reduced 62.84%	972 $26,000
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $67,468 - $83,804	-2,525 Reduced 49.11%	2,616 $80,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $82,254 - $107,118	3,406 Added 196.31%	5,141 $135,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $554,558 - $808,653	-31,331 Reduced 94.75%	1,735 $44,000
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $491,021 - $608,915	24,308 Added 277.55%	33,066 $689,000
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $149,674 - $217,986	8,758 New	8,758 $208,000
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $8,912 - $14,308	-289 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $12,340 - $16,342	289 New	289 $15,000
Q2 2018 Aug 15, 2018	SELL	$44.1 - $59.85 $4,410 - $5,985	-100 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $3,715 - $4,690	100 New	100 $5,000
Q4 2017 Feb 09, 2018	SELL	$36.4 - $42.6 $104,577 - $122,389	-2,873 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $105,582 - $142,644	2,873	2,873 $115,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Supernus Pharmaceuticals, Inc. Transaction History